Skip to content
TheChatArchiveThe Chat Archive
Geminigemini-2.5-flash-lite-preview-06-17-thinking· GoogleHugging Face LMArena Human Preference 140K

tirzepatide vs retatrutide after 1 year

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Claudeclaude-3-5-haiku-20241022’s answer.
  1. User

    tirzepatide vs retatrutide after 1 year

  2. Gemini Assistant

    Okay, let's compare Tirzepatide (Mounjaro/Zepbound) and Retatrutide based on data available around the one-year mark from clinical trials.

    Key Difference:

    • Tirzepatide: A dual agonist targeting GIP and GLP-1 receptors.
    • Retatrutide: A triple agonist targeting GIP, GLP-1, and Glucagon receptors. This addition of the glucagon pathway is key to its potentially enhanced effects.

    Here's a breakdown of how they compare after approximately one year of treatment, primarily based on Phase 2 and early Phase 3 trial data:

    1. Efficacy (Weight Loss):

    • Tirzepatide: In Phase 3 trials (like SURMOUNT-2 and SURMOUNT-3 for obesity), Tirzepatide at its highest approved dose (15mg) resulted in significant weight loss after about 1 year (or 72 weeks). Average weight loss was often reported in the range of 15% to over 20% from baseline, depending on the specific trial population and dosing schedule.

    • Retatrutide: In its pivotal Phase 2 trial (which included data up to 48 or 68 weeks, covering the one-year mark), Retatrutide demonstrated even greater weight loss compared to Tirzepatide (which was included as a comparator arm in this specific trial). At the highest tested doses, average weight loss reached up to 24% from baseline.

      • Summary: Based on available trial data comparing them (specifically the SURMOUNT-4 trial which added a Retatrutide arm), Retatrutide has shown a potentially higher degree of weight loss at the one-year mark compared to Tirzepatide.

    2. Efficacy (Diabetes Control - HbA1c Reduction):

    • Tirzepatide: Highly effective in improving glycemic control in people with type 2 diabetes. Reductions in HbA1c of over 2% were commonly seen in trials like SURPASS-4 at the one-year point.

    • Retatrutide: Also showed significant reductions in HbA1c in clinical trials, comparable to or potentially slightly exceeding Tirzepatide in some head-to-head comparisons within trials. Reductions were also substantial, often exceeding 2%.

      • Summary: Both drugs are highly effective for improving blood sugar control in type 2 diabetes after one year. Retatrutide might offer a slight edge, but both are very potent.

    3. Side Effects:

    • Tirzepatide: The most common side effects are gastrointestinal (GI) related and often dose-dependent, including nausea, vomiting, diarrhea, constipation, and decreased appetite. These tend to be most prominent when starting the medication or increasing the dose and often improve over time.

    • Retatrutide: Shares similar GI side effects (nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite). Some reports and trial data suggest the incidence or severity of these GI side effects might be slightly higher with Retatrutide, potentially due to the triple mechanism including glucagon. Other potential side effects noted include hair loss and fatigue. Long-term effects, especially related to the glucagon component, are still under close observation in ongoing trials.

      • Summary: Both have similar primary side effect profiles (GI-related). Retatrutide may potentially have a slightly higher rate or intensity of these side effects, but requires more long-term data for definitive comparison.

    4. Clinical Status & Availability (As of early/mid-2024):

    • Tirzepatide: Approved by regulatory bodies like the FDA. Available by prescription under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management).
    • Retatrutide: Still in late-stage clinical trials (Phase 3). It is not yet approved by the FDA or other regulatory agencies. Data is still being gathered, and submission for approval is anticipated.

    Conclusion After 1 Year:

    Based on trial data available around the one-year mark:

    • Retatrutide has shown potentially superior efficacy for weight loss compared to Tirzepatide.
    • Both drugs demonstrate high efficacy in improving glycemic control (HbA1c) for type 2 diabetes.
    • Side effect profiles are similar, primarily GI-related, with Retatrutide possibly having a slightly higher incidence.
    • Tirzepatide is currently available by prescription, while Retatrutide is still investigational and not yet approved for medical use.

    The choice between them (once Retatrutide is approved) will depend on individual response, tolerability, specific health goals, and physician recommendations. Tirzepatide is the established, approved option right now, offering significant benefits. Retatrutide represents a potentially more potent next step, pending regulatory review and further long-term safety data.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.